Elizabeth Kemmerer

Array ( [id] => 20491462 [patent_doc_number] => 12533317 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Stem cell-derived exosomes containing pain regulators, and uses thereof [patent_app_type] => utility [patent_app_number] => 17/907653 [patent_app_country] => US [patent_app_date] => 2021-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 0 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17907653 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18335099 [patent_doc_number] => 20230127047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES [patent_app_type] => utility [patent_app_number] => 17/914612 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18306789 [patent_doc_number] => 20230110689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => AGONIST COMBINATION [patent_app_type] => utility [patent_app_number] => 17/906871 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18896 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17906871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17168844 [patent_doc_number] => 20210322514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING MYELOFIBROSIS [patent_app_type] => utility [patent_app_number] => 17/210037 [patent_app_country] => US [patent_app_date] => 2021-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56102 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20343360 [patent_doc_number] => 12467083 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-11 [patent_title] => Primer sets for detection of mycoplasma pneumoniae bacteria, method for detection of mycoplasma pneumoaniae infection, use of a primer set for detection of mycoplasma pneumoniae infection [patent_app_type] => utility [patent_app_number] => 17/905572 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 0 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096953 [patent_doc_number] => 20210284744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/201698 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17201698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096931 [patent_doc_number] => 20210284722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION [patent_app_type] => utility [patent_app_number] => 17/196256 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667561 [patent_doc_number] => 12180289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Binding proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/194144 [patent_app_country] => US [patent_app_date] => 2021-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 98 [patent_figures_cnt] => 99 [patent_no_of_words] => 82686 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17194144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19651289 [patent_doc_number] => 12173058 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-24 [patent_title] => Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta [patent_app_type] => utility [patent_app_number] => 17/187168 [patent_app_country] => US [patent_app_date] => 2021-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13404 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17187168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356804 [patent_doc_number] => 20220017600 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/184692 [patent_app_country] => US [patent_app_date] => 2021-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17184692 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18267241 [patent_doc_number] => 20230088483 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => USE OF RECOMBINANT CYTOKINE GENE DERIVED PROTEIN OR FRAGMENT THEREOF [patent_app_type] => utility [patent_app_number] => 17/801571 [patent_app_country] => US [patent_app_date] => 2021-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801571 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254222 [patent_doc_number] => 20230081261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/760470 [patent_app_country] => US [patent_app_date] => 2021-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18251639 [patent_doc_number] => 20230078678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS [patent_app_type] => utility [patent_app_number] => 17/760427 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19737190 [patent_doc_number] => 12213997 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-04 [patent_title] => Compositions and methods for supporting nucleus pulposus (NP) cell phenotype and biosynthesis [patent_app_type] => utility [patent_app_number] => 17/165011 [patent_app_country] => US [patent_app_date] => 2021-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 27 [patent_no_of_words] => 29278 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007132 [patent_doc_number] => 20210238293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => METHOD OF TREATING IGG4-RELATED DISEASE [patent_app_type] => utility [patent_app_number] => 17/162934 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254855 [patent_doc_number] => 20230081894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISORDER, COMPRISING MESENCHYMAL STEM CELLS OR INSULIN SECRETED BY MESENCHYMAL STEM CELLS [patent_app_type] => utility [patent_app_number] => 17/912913 [patent_app_country] => US [patent_app_date] => 2021-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007084 [patent_doc_number] => 20210238245 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => Bi-functional fusion proteins comprised of TGF-B and immune checkpoint domains [patent_app_type] => utility [patent_app_number] => 17/248288 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17248288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839488 [patent_doc_number] => 20210147500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => GROWTH DIFFERENTIATION FACTOR 15 FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/148761 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292265 [patent_doc_number] => 20210388104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/140398 [patent_app_country] => US [patent_app_date] => 2021-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22029 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17140398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16914013 [patent_doc_number] => 20210187105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS [patent_app_type] => utility [patent_app_number] => 17/139772 [patent_app_country] => US [patent_app_date] => 2020-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12805 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17139772 [rel_patent_id] =>[rel_patent_doc_number] =>)